Fig. 2From: MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancerSchematic representation of the autoregulatory loop between P53, MDM2, and MDMX and pharmacological inhibitors. The picture shows the main molecular links between P53, MDM2, and MDMX together with the MDM2 and MDMX inhibitors under clinical evaluation and the key compounds used in clinical studies for combination therapyBack to article page